estim
million
peopl
worldwid
develop
tuberculosi
tb
million
hivneg
peopl
die
diseas
world
health
organ
lack
rapid
accur
diagnost
tool
contribut
estim
million
case
tb
went
unreport
tdr
find
sa
smear
microscopi
first
line
tb
detect
low
variabl
sensit
steingart
et
al
aber
et
al
urbanczik
convent
cultur
solid
media
sensit
requir
week
result
lee
et
al
et
al
although
convent
liquid
cultur
mycobacteria
growth
indic
tube
mgit
becton
dickinson
microbiolog
system
typic
sensit
greater
time
result
still
week
result
individu
lost
followup
treatment
delay
stall
et
al
use
molecular
method
nucleic
acid
amplif
test
naat
may
promis
faster
result
high
sensit
specif
xpert
mtbrif
assay
cepheid
sunnyval
ca
usa
autom
molecular
method
base
pcr
initi
demonstr
studi
found
sensit
smearneg
cultureposit
tb
specif
boehm
et
al
boehm
et
al
cochran
review
found
sensit
smearneg
cultureposit
tb
specif
steingart
et
al
howev
xpert
mtbrif
requir
continu
suppli
electr
hefti
invest
equip
longterm
mainten
plan
tblamp
new
commerci
avail
manual
molecular
tb
detect
method
base
novel
loopmedi
isotherm
amplif
platform
lamp
manufactur
eiken
chemic
co
japan
lamp
attract
diagnost
platform
take
less
h
perform
requir
minim
instrument
gener
fluoresc
result
detect
nake
eye
notomi
et
al
furthermor
shown
potenti
crossdiseas
platform
assay
develop
malaria
african
trypanosomiasi
sever
acut
respiratori
syndrom
influenza
kuboki
et
al
poon
et
al
poon
et
al
poon
et
al
tblamp
assay
requir
minim
instrument
form
heat
block
addit
potenti
higher
throughput
test
sampl
per
test
run
boehm
et
al
vassal
et
al
full
descript
tblamp
procedur
found
recent
world
health
organ
polici
guidanc
polici
guidanc
studi
aim
determin
accuraci
tblamp
singl
raw
sputum
sampl
comparison
convent
method
xpert
mtbrif
assay
perform
qualityassur
tb
refer
laboratori
tb
refer
laboratori
select
four
urban
centr
cape
town
south
africa
lima
peru
ho
chi
minh
citi
vietnam
rio
de
janeiro
brazil
refer
laboratori
select
enrol
nation
intern
qualiti
assur
programm
undergon
laboratori
assess
find
prior
select
studi
approv
institut
review
board
countri
inform
consent
obtain
particip
addit
particip
may
receiv
better
standard
diagnost
care
use
addit
cultur
clinician
blind
result
tblamp
impact
patient
care
adult
year
symptom
suggest
pulmonari
tb
defin
nation
tb
programm
enrol
consecut
abl
provid
two
sputum
sampl
least
ml
receiv
tb
treatment
preced
day
two
sputum
sampl
obtain
remov
tblamp
approxim
direct
zn
andor
lightemit
diod
led
fluoresc
microscopi
fm
smear
figur
tblamp
technician
blind
smear
result
vice
versa
remain
sputum
process
hydroxid
use
solid
cultur
medium
mgit
liquid
cultur
siddiqi
rueschgerd
first
posit
cultur
two
perform
per
sampl
two
sampl
per
individu
underw
confirm
mycobacterium
tuberculosi
mtb
complex
antigen
detect
capilia
tb
taun
laboratori
hillemann
et
al
scanti
posit
cultur
defin
posit
mgit
day
inocul
coloni
cultureposit
tb
case
diagnos
particip
either
two
scanti
nonscanti
posit
mtb
cultur
result
consist
previou
analysi
molecular
tb
diagnost
boehm
et
al
boehm
et
al
nontubercul
mycobacteria
ntm
mix
case
analyz
separ
sampl
cultureposit
tb
case
classifi
smearposit
smearneg
base
singl
smear
test
perform
sputum
smearposit
tb
sampl
requir
one
acidfast
bacilli
per
field
zn
per
field
fm
scanti
grade
higher
follow
recommend
world
health
organ
smearneg
tb
sampl
acidfast
bacilli
detect
zn
fm
whatsoev
found
cultur
test
cultureposit
tb
case
sampl
particip
cultur
neg
posit
smear
analyz
separ
particip
smear
result
neg
four
cultur
neg
two
cultur
contamin
remain
neg
consid
bacteriolog
neg
tb
bacteriolog
neg
particip
found
tblampposit
either
sputum
specimen
sought
clinic
laboratori
followup
week
bacteriolog
neg
particip
found
tblampneg
also
follow
wherev
programmat
possibl
nontb
case
defin
particip
bacteriolog
neg
tb
treatment
prescrib
base
adjunct
diagnost
chest
xray
andor
symptom
enrol
followup
week
bacteriolog
neg
particip
treat
empir
enrol
followup
consid
clinic
diagnos
tb
decis
discret
physician
subject
local
variat
initi
bacteriolog
neg
posit
cultur
followup
reclassifi
cultureposit
tb
laboratori
confirm
either
unimprov
chest
xray
ie
physician
compar
followup
chest
xray
initi
chest
xray
found
abnorm
wors
nonremit
symptom
ie
physician
describ
symptom
wors
followup
reclassifi
possibl
tb
analyz
separ
tblamp
technician
could
determin
fluoresc
readout
whether
tblamp
posit
neg
second
reader
ask
make
determin
second
read
also
indetermin
second
tblamp
test
repeat
sputum
sampl
wherev
possibl
run
tblamp
test
one
time
includ
neg
posit
control
neg
control
posit
indic
potenti
dna
contamin
test
run
must
repeat
decontamin
procedur
posit
control
neg
indic
probabl
reagent
degrad
test
run
must
repeat
new
reagent
overal
indetermin
rate
indic
lack
clear
result
need
repetit
test
caus
perform
tblamp
singl
raw
sputum
sampl
evalu
refer
standard
two
direct
zn
smear
two
direct
fm
smear
four
cultur
per
patient
tblamp
test
perform
two
sampl
submit
per
particip
correl
result
account
use
bootstrap
sampl
cluster
set
two
sampl
cluster
obtain
exact
standard
error
calcul
correct
confid
interv
ci
singl
raw
sampl
perform
xpert
mtbrif
assay
evalu
molecular
test
comparison
tblamp
peru
south
africa
assay
alreadi
avail
use
xpert
mtbrif
assay
perform
freshli
concentr
sputum
wherea
brazil
vietnam
xpert
assay
perform
sputum
frozen
month
xpert
mtbrif
assay
perform
concentr
first
sputum
sampl
collect
accord
manufactur
instruct
figur
peru
assay
perform
third
sputum
sampl
provid
first
sputum
sampl
third
sampl
underw
direct
zn
fm
smear
concentr
xpert
mtbrif
test
brazil
vietnam
concentr
ml
remaind
first
sampl
collect
frozen
test
xpert
mtbrif
month
sampl
report
posit
mtb
autom
output
xpert
mtbrif
consid
posit
sampl
report
mtbneg
consid
neg
error
invalid
result
valu
consid
indetermin
inelig
sensitivityspecif
analysi
ci
obtain
use
binomi
distribut
blind
deem
unnecessari
given
autom
natur
test
januari
decemb
elig
particip
enrol
across
four
site
tabl
result
particip
exclud
analysi
follow
reason
two
two
contamin
cultur
five
cultureposit
miss
result
singl
posit
cultur
day
coloni
two
miss
smear
result
three
found
cultureposit
ntm
followup
across
site
cultureposit
tb
case
nontb
particip
clinic
diagnos
tb
possibl
tb
particip
sputum
sampl
primari
analysi
figur
particip
ntm
mix
infect
analyz
separ
tabl
also
analyz
separ
nine
fm
smearposit
cultureneg
individu
followup
rate
among
individu
posit
tblamp
neg
smearcultur
result
followup
rate
among
particip
neg
result
test
tabl
overal
followup
rate
neg
smearcultur
result
south
africa
peru
vietnam
brazil
particip
posit
tblamp
neg
smearcultur
follow
none
neg
test
follow
due
programmat
restrict
overal
tblamp
indetermin
rate
two
tblamp
test
perform
could
interpret
two
read
four
posit
result
neg
control
indic
like
dna
contamin
run
assay
clear
posit
neg
result
repetit
tblamp
assay
sputum
particip
cultureposit
tb
two
sputum
sampl
sampl
sampl
test
posit
tblamp
give
sensit
ci
sensit
ci
ci
direct
zn
smearposit
smearneg
tb
sampl
respect
tabl
overal
result
classifi
use
direct
fm
smear
similar
direct
fm
result
includ
peru
vietnam
brazil
nine
hundr
fortytwo
sputum
sampl
nontb
particip
test
neg
tblamp
give
overal
specif
ci
tabl
inclus
followup
inform
made
greatest
impact
brazil
specif
ci
ci
exclus
followup
ie
inclus
initi
clinic
laboratori
find
whether
individu
immedi
put
treatment
vietnam
specif
also
improv
inclus
followup
ci
specif
peru
ci
south
africa
also
ci
site
specif
similar
irrespect
whether
followup
data
consid
south
africa
signific
number
hivposit
individu
overal
sensit
tblamp
sputum
sampl
cultureposit
hivposit
particip
ci
smear
statu
hivposit
particip
sensit
ci
smearposit
sampl
ci
smearneg
sampl
perform
tblamp
compar
xpert
mtbrif
tabl
studi
overal
sensit
smearposit
tb
case
ci
tblamp
ci
xpert
mtbrif
p
pearson
test
sensit
smearneg
tb
case
ci
tblamp
ci
xpert
mtbrif
p
specif
ci
tblamp
ci
xpert
mtbrif
p
xpert
mtbrif
indetermin
rate
studi
success
demonstr
perform
tblamp
assay
tblamp
reliabl
detect
nearli
smearposit
tb
case
roughli
half
smearneg
tb
case
singl
raw
sputum
sampl
studi
tb
refer
laboratori
signific
differ
sensit
specif
found
tblamp
compar
xpert
mtbrif
use
four
direct
smear
four
cultur
refer
standard
brazil
lowest
specif
rate
tblamp
xpert
mtbrif
well
least
followup
inform
given
programmat
capabl
followup
ask
particip
posit
tblamp
bacteriolog
neg
result
followup
rate
result
signific
improv
tblamp
specif
exclud
followup
includ
followup
direct
followup
perform
particip
xpert
mtbrifposit
bacteriolog
neg
result
furthermor
use
imperfect
standard
deleteri
effect
assay
higher
specif
although
could
confirm
possibl
specimen
decontamin
cultur
brazil
perform
use
naoh
recommend
would
destroy
weakli
grow
mycobacteria
therebi
lower
cultur
sensit
kent
kubica
global
laboratori
initi
hypothesi
support
high
number
smearposit
cultureneg
result
found
brazil
final
laboratori
brazil
lower
sensit
use
fm
standard
zn
opposit
would
expect
base
previou
metaanalysi
two
method
steingart
et
al
exclud
brazil
specif
would
tblamp
across
three
countri
xpert
mtbrif
specif
xpert
mtbrif
agre
data
report
literatur
steingart
et
al
peru
unusu
high
tblamp
sensit
zn
smearneg
vietnam
unusu
low
tblamp
sensit
fm
smearneg
variat
may
reflect
variabl
smear
perform
one
laboratori
anoth
variabl
site
site
seen
xpert
mtbrif
well
support
conclus
conclus
studi
limit
complet
followup
standard
protocol
possibl
find
contribut
grow
literatur
perform
molecular
assay
intend
popul
given
find
studi
laboratori
perform
tblamp
approach
xpert
mtbrif
studi
recommend
set
intend
use
evalu
expect
benefit
use
manual
techniqu
may
give
tblamp
potenti
enter
market
lower
cost
autom
counterpart
vassal
et
al
hope
limit
infrastructur
need
reliabl
power
heat
block
min
make
possibl
run
assay
decentr
set
furthermor
higher
throughput
assay
test
per
batch
run
may
accommod
laboratori
moder
high
workload
level
health
system
clinic
evalu
assay
develop
support
find
author
conflict
interest
declar
